Pirfenidone - Roche

Drug Profile

Pirfenidone - Roche

Alternative Names: AMR-69; Deskar; Esbriet; Etuary; F-647; Pirespa; RO-0220912; S-7701

Latest Information Update: 05 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KDL Gmbh; Marnac
  • Developer AFT Pharmaceuticals; Beijing Continent Pharmaceutical; Il Dong; InterMune; Justus Liebig University Giessen; Roche; Shanghai Genomics; Shionogi; Stanford University; University of California at San Francisco
  • Class Anti-inflammatories; Antifibrotics; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Interstitial lung diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis
  • Phase II Acute lung injury; Graft-versus-host disease; Heart failure; Interstitial lung diseases; Lung transplant rejection; Pulmonary fibrosis
  • Preclinical Diabetic nephropathies
  • Discontinued Glomerulonephritis; Multiple sclerosis; Peritoneal fibrosis; Renal fibrosis; Retinal disorders; Scleroderma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 May 2018 Justus Liebig Universitat Giessen and Roche temporarily suspends phase II trial in Pulmonary fibrosis in Germany (PO) (EudraCT2014-000861-32)
  • 27 Apr 2018 Genentech initiates a phase II trial in Interstitial lung disease in USA (PO) (NCT03473340)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top